Nabriva Therapeutics

Link
nabriva.com
Phone
+1 (610) 816-6640
Address
1000 Continental Drive, Suite 450
E-mail
office@nabriva.com
Country
USA
Headquarters
King of Prussia, PA 19406
Stage of the project
Second stage
Total Raised
$22,000,000
Description

Nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.